SCHEMBL3607181

SCHEMBL3607181

COc1ccc(OC)c(NCC=C(C)CCC=C(C)C)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 1/20 0.46
▸ PPARA Q07869 1/20 0.46
▸ PTGES O14684 4/20 0.45
▸ TRPV1 Q8NER1 4/20 0.44
▸ MAPT P10636 1/20 0.43
▸ MTNR1A P48039 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ OPRD1 P41143 1/20 0.42
▸ BCHE P06276 1/20 0.41
▸ HDAC3 O15379 1/20 0.41
▸ HDAC4 P56524 1/20 0.41
▸ HDAC1 Q13547 1/20 0.41
▸ HDAC7 Q8WUI4 1/20 0.41
▸ HDAC2 Q92769 1/20 0.41
▸ HDAC10 Q969S8 1/20 0.41
▸ HDAC11 Q96DB2 1/20 0.41
▸ HDAC8 Q9BY41 1/20 0.41
▸ HDAC6 Q9UBN7 1/20 0.41
▸ HDAC9 Q9UKV0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3607179 1.00 PPARG (0.46) PPARGPPARAPTGESTRPV1MAPT
SCHEMBL8223338 0.83 PTGES (0.47) PTGESTRPV1MAPTMTNR1AHDAC3
SCHEMBL3595116 0.83 TRPV1 (0.46) PTGESTRPV1
SCHEMBL3595119 0.83 TRPV1 (0.46) PTGESTRPV1
SCHEMBL3590181 0.82 PTGES (0.47) PTGESTRPV1MAPTMTNR1AHDAC3
SCHEMBL8222381 0.82 PTGES (0.47) PTGESTRPV1MTNR1AHDAC3HDAC4
SCHEMBL3609256 0.82 PTGES (0.47) PTGESTRPV1MAPTMTNR1AHDAC3
SCHEMBL8223345 0.82 PTGES (0.47) PTGESTRPV1MAPTMTNR1AHDAC3
SCHEMBL3599814 0.82 ALOX5 (0.45) PTGESTRPV1KMT2A
SCHEMBL3599812 0.82 ALOX5 (0.45) PTGESTRPV1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041665-A1 N-PHENYL-PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS NOSCIRA, S.A. (ES) 2010-02-18 — — US disclosed
EP-2057114-A1 N-PHENYL-PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS NOSCIRA, S.A. (ES) 2009-05-13 — — EP disclosed
WO-2008015240-A1 N-PHENYL-PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS NOSCIRA, S.A. (ES) 2008-02-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041665-A1 N-PHENYL-PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS PNMT, PSEN1, SNCA PPARG 1070/4885PPARA 452/4885PTGES 410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback